Celgene Investors Seek Cert. In Suit Over Drug Disclosures
Celgene investors have asked a New Jersey federal judge for class certification in their suit accusing the biopharmaceutical company of artificially inflating its share price by failing to disclose timeline and...To view the full article, register now.
Already a subscriber? Click here to view full article